share_log

NovAccess Global Announces Initial Fireside Chat With Glioblastoma Patient Advocate

NovAccess Global Announces Initial Fireside Chat With Glioblastoma Patient Advocate

NovAccess Global 宣布与胶质母细胞瘤患者倡导者进行首次炉边交谈
Accesswire ·  2022/11/22 21:05

Topic: Benefits of Immunotherapies Versus Conventional Chemotherapy for Patients and Their Support Networks

主题:免疫疗法与传统化疗对患者及其支持网络的好处

CLEVELAND, OH / ACCESSWIRE / November 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its latest monthly installment in a series of fireside chat interviews, with additional sessions to be made available as company developments arise. Interviews are intended to cover important and timely topics relating to the Company, its platform technologies and the global healthcare and business environments.

俄亥俄州克利夫兰/ACCESSWIRE/2022年11月22日为脑瘤患者开发新型免疫疗法的生物医药公司NovAccess Global Inc.(OTCQB:XSNX)今天宣布,将在一系列炉边聊天访谈中推出其最新的月度分期付款,随着公司发展,还将提供额外的会议。访谈旨在涵盖与该公司、其平台技术以及全球医疗保健和商业环境相关的重要和及时的话题。

The fireside chat announced today is an interview conducted by NovAccess Global CEO Dr. Dwain Irvin with cancer patient advocate Cori Freeman. The interview is being streamed for public viewing over the Internet and can be accessed via the News tab of the Investors section of the NovAccess Global website at and on all of the Company's social media feeds.

今天宣布的炉边谈话是NovAccess全球首席执行官Dwain Irvin博士与癌症患者权益倡导者Cori Freeman进行的采访。访谈将通过互联网流媒体供公众观看,并可通过NovAccess全球网站投资者部分的新闻选项卡在该公司的所有社交媒体订阅源上访问。

During the interview made available today, the speakers highlight:

在今天提供的采访中,演讲者强调:

  • Journeys through treatment for patients, their support systems and families
  • Failures and challenges of traditional/conventional chemotherapy, where cancers often "came back with a vengeance"
  • Choosing the appropriate treatment options for brain tumor/glioblastoma patients
  • Benefits of building up the immune system with immunotherapy when fighting cancer
  • Integrative approaches with immunotherapy
  • NovAccess Global advancing where no measurable survivability and quality of life improvements have been achieved in 50 years for glioblastoma/brain tumors
  • Hope found with glioblastoma immunotherapy research by Dr. Dwain Irvin
  • Success stories of recovery after traditional chemotherapy using immunotherapy
  • Improving the quality of life for patients and accelerating the path to recovery
  • 20 years of clinical trials as the foundation for NovAccess Global's lead drug candidate TLR-AD1 which recently received FDA approval for Orphan Drug Designation
  • NovAccess Global leveraging new technologies, additional assets, novel therapies and diagnostic data as it pursues IND for new clinical trials
  • 患者、他们的支持系统和家人的治疗之旅
  • 传统/传统化疗的失败和挑战--癌症往往“卷土重来”
  • 为脑瘤/胶质母细胞瘤患者选择合适的治疗方案
  • 在抗击癌症时通过免疫疗法增强免疫系统的好处
  • 与免疫治疗相结合的方法
  • NovAccess全球进步,50年来胶质母细胞瘤/脑瘤的存活率和生活质量没有实现可衡量的改善
  • Dwain Irvin博士的胶质母细胞瘤免疫治疗研究发现了希望
  • 传统免疫疗法化疗后康复的成功案例
  • 改善患者的生活质量,加快康复之路
  • 20年的临床试验是NovAccess Global的主要候选药物TLR-AD1的基础,该药最近获得了FDA对孤儿药物指定的批准
  • NovAccess Global利用新技术、更多资产、新疗法和诊断数据进行新的临床试验

NovAccess Global Fireside Chat Series Schedule:

NovAccess全球炉边聊天系列时间表:

The series will include interviews on a monthly basis over the next four months. Interviews will be made available by NovAccess Global as detailed below:

该系列将在接下来的四个月里每月进行一次采访。访谈将由NovAccess Global提供,详情如下:

October 6, 2022 - NovAccess Global Board Member Perspectives - Opportunities for the Biomedical Field and for Shareholders

2022年10月6日-NovAccess全球董事会成员展望-生物医学领域和股东的机遇

Speakers: Select Executive and Non-Executive members of the Company's Board of Directors

演讲者:公司董事会部分执行和非执行成员

November 18, 2022 - Patient Advocacy

2022年11月18日-患者权益

Speakers: Dr. Dwain Irvin, Ph.D., MPH, CEO of NovAccess Global; cancer patient advocate Cori Freeman

演讲者:Dwain Irvin博士,博士,公共卫生硕士,NovAccess Global首席执行官;癌症患者权益倡导者科里·弗里曼

December 2022 - Immunotherapy Advantages Over Surgical Treatment

2022年12月-免疫治疗优于外科治疗

Speaker: Dr. Christopher Wheeler, Ph.D., President of StemVax Therapeutics Inc., a division of NovAccess Global

演讲者:克里斯托弗·惠勒博士,博士,总裁,StemVax治疗公司,NovAccess全球公司的一个部门

January 2023 - The Glioblastoma and Brian Tumor Market

2023年1月-胶质母细胞瘤和脑肿瘤市场

Speaker: Dr. Dwain Irvin, Ph.D., MPH, CEO of NovAccess Global

演讲者:Dwain Irvin博士,博士,公共卫生硕士,NovAccess Global首席执行官

The interviews will be streamed for public viewing over the Internet and can be accessed on the dates provided in this press release through links made available on the NovAccess Global website at and on all of the Company's social media feeds.

访谈将通过互联网向公众播放,并可在本新闻稿中提供的日期通过NovAccess全球网站和该公司所有社交媒体订阅源上的链接进行访问。

About NovAccess Global

关于NovAccess Global

NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global是一家加速新型癌症诊断和治疗的生物医药公司。我们的目标是发现、开发和向市场推出新颖和创新的药物和医疗设备,以提高癌症和神经科患者的护理质量。

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.

NovAccess Global目前正在开发一种癌症疫苗疗法,以增强患者对脑瘤的免疫反应。我们公司有一种新的免疫治疗方法来治疗患有胶质母细胞瘤的脑肿瘤患者,胶质母细胞瘤是最常见的成人脑瘤,确诊后中位生存期为15个月。我们的专利技术旨在将基于树突状细胞的免疫治疗方法与Toll样受体(TLR)佐剂的独特组合TLR-AD1相结合,以帮助促进针对患者肿瘤的增强免疫反应。我们的平台技术专注于通过利用患者肿瘤特有的抗原来增强患者的免疫细胞,以对抗他们独特的癌症。这是一项有意义的技术,可以显著提高许多脑瘤患者的生活质量和预后。欲了解更多信息,请访问novacesslobal.com。

Forward-Looking Statement

前瞻性陈述

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

本新闻稿包含修订后的1933年证券法第27A节和修订后的1934年证券交易法第21E节所指的“前瞻性陈述”,这些前瞻性陈述是根据1995年私人证券诉讼改革法的安全港条款作出的。“前瞻性陈述”描述未来的预期、计划、结果或战略,通常以“可能”、“未来”、“计划”或“计划”、“将”或“应该”、“预期”、“预期”、“草案”、“最终”或“预计”等词语开头。请注意,此类陈述会受到多种风险和不确定因素的影响,这些风险和不确定因素可能会导致未来的情况、事件或结果与前瞻性陈述中预测的情况、事件或结果大不相同,包括由于各种因素,实际结果可能与前瞻性陈述中预测的结果大不相同的风险,以及公司向证券交易管理委员会提交的披露或文件中确定的其他风险。需要进一步提醒的是,细价股和NovAccess Global Inc.等小公司的股票本质上是不稳定和有风险的,任何投资者都不应购买这种股票,除非他们能够负担得起全部投资的损失。公司没有义务更新任何前瞻性陈述,以反映事件或情况发生之后的情况。

This press release and the interviews to be published as part of the NovAccess Global fireside chat series are for informational purposes only and should not be considered investment advice, an offer to sell, or a solicitation of an offer to buy any security. Interview participants have agreed to participate in this event series and no compensation will be paid or furnished to them or their respective organizations. Participation does not represent an offer to buy or sell any security to or from any person or other entity through their platforms. Prior to making any investment or subscribing to any of the platforms that may be associated with the fireside chat series and re-distribution of related content, listeners/viewers are encouraged to consult with professional financial, legal advisor and tax advisors to assist in due diligence as may be appropriate in determining the risk associated with any investment.

本新闻稿和采访将作为NovAccess全球炉边聊天系列的一部分发布,仅供参考和不应被视为投资建议、出售要约或征求购买任何证券的要约。面试参与者已同意参加这一系列活动,不会向他们或他们各自的组织支付或提供任何补偿。参与并不代表通过任何人或其他实体的平台向任何人或其他实体购买或出售任何证券。在进行任何投资或订阅任何可能与炉边聊天系列相关的平台并重新分发相关内容之前,鼓励听众/观众咨询专业财务、法律顾问和税务顾问,以协助进行适当的尽职调查,以确定与任何投资相关的风险。

Investor Relations Contact:

投资者关系联系人:

Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com

乔丹·达罗
Darrow Associates
631-766-4528
邮箱:jdarrow@darrowir.com

SOURCE: NovAccess Global Inc.

资料来源:NovAccess Global Inc.


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发